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Abstract
SUMO is a ubiquitin-like protein that is post-translationally attached to one or more lysine residues on target proteins.
Despite having only 18% sequence identity with ubiquitin, SUMO contains the conserved bbabbab fold present in
ubiquitin. However, SUMO differs from ubiquitin in having an extended N-terminus. In S. pombe the N-terminus of SUMO/
Pmt3 is significantly longer than those of SUMO in S. cerevisiae, human and Drosophila. Here we investigate the role of this
N-terminal region. We have used two dimensional gel electrophoresis to demonstrate that S. pombe SUMO/Pmt3 is
phosphorylated, and that this occurs on serine residues at the extreme N-terminus of the protein. Mutation of these
residues (in pmt3-1) results in a dramatic reduction in both the levels of high Mr SUMO-containing species and of total
SUMO/Pmt3, indicating that phosphorylation of SUMO/Pmt3 is required for its stability. Despite the significant reduction in
high Mr SUMO-containing species, pmt3-1 cells do not display an aberrant cell morphology or sensitivity to genotoxins or
stress. Additionally, we demonstrate that two lysine residues in the N-terminus of S. pombe SUMO/Pmt3 (K14 and K30) can
act as acceptor sites for SUMO chain formation in vitro. Inability to form SUMO chains results in aberrant cell and nuclear
morphologies, including stretched and fragmented chromatin. SUMO chain mutants are sensitive to the DNA synthesis
inhibitor, hydroxyurea (HU), but not to other genotoxins, such as UV, MMS or CPT. This implies a role for SUMO chains in the
response to replication arrest in S. pombe.
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Introduction
Post-translational modification is an efficient and rapid way of
controlling the activity of proteins. A variety of species have been
identified that can be attached post-translationally to proteins. In
many cases, modification involves small species, e.g. in the
phosphorylation, acetylation and methylation of proteins, while
in others the modifying species are larger, e.g. in the case of
ubiquitination and sumoylation, which involve the proteins
ubiquitin and SUMO respectively e.g. [1,2].
SUMO is a member of the Ubl (ubiquitin-like) family of post-
translational modifiers. Although it has only 18% sequence
identity with ubiquitin, its structure resembles that of ubiquitin,
in that it contains the conserved ubiquitin bbabbab fold [3,4].
Ubiquitin comprises 76 aa, while SUMO is larger, having an
extended N-terminus (in the order of 15–30 aa) that is not present
in ubiquitin. The major role of ubiquitin is in targeting proteins for
proteasome-mediated proteolysis (reviewed in [5]). However,
ubiquitin also has important roles in modifying the function of
individual proteins required for specific processes, e.g. ubiquitina-
tion of PCNA (proliferating cell nuclear antigen) is required for
bypass of replication blocking lesions in DNA [6,7,8]. SUMO
modification has a variety of cellular functions, including roles in
transcription, DNA damage responses, the cell cycle and nuclear
transport e.g. [9,10,11]. Recently it has been shown to be required
for STUbL- (SUMO-targeted ubiquitin ligase)-dependent ubiqui-
tination of target proteins e.g. [12,13,14].
The process of sumoylation resembles that of ubiquitination
(reviewed in [15]). Like ubiquitin, SUMO is produced as a
precursor protein that needs to be cleaved to the mature form by
one or more specific SUMO proteases (Ulps). This processing
reveals a GG motif at the C-terminus of SUMO, which is required
for its subsequent activation and conjugation to target proteins.
Mature SUMO is first activated by a heterodimeric activator
protein via the formation of a thioester linkage. It is then
transferred to a SUMO conjugator, again forming a thioester link.
From here, SUMO is attached to one or more lysine residues on
the target protein via an e2amino bond. In many cases, the
acceptor lysine is present within the context yKxE, where y is a
bulky hydrophobic amino acid and x is any residue. In some
instances attachment of SUMO to target proteins is enhanced by
one of relatively few SUMO ligases.
It is well documented that ubiquitin forms chains (e.g. [16]).
This can occur through a number of lysine residues within
ubiquitin, predominantly K6, K29, K48 and K63. Initial reports
on SUMO modification suggested that, unlike ubiquitin, SUMO
did not form chains. However, several findings have established
that SUMO is capable of forming chains, both in vitro and in vivo
[17,18,19,20]. Despite evidence for their existence in vivo, the
biological role of SUMO chains is less obvious. An S. cerevisiae
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mutant (smt3-allR) in which all potential SUMO acceptor lysines
have been mutated to alanine, shows little phenotype during
vegetative growth [20]. More recently it has been demonstrated
that SUMO chains can interact with STUbLs (via SIMs –
SUMO-interacting motifs) [21], implying that they can act as a
signal to target proteins for ubiquitin-mediated proteolysis.
The process of sumoylation is generally conserved between
eukaryotic organisms. In S. pombe, SUMO is encoded by the pmt3
gene [22]. The ubiquitin-like region of S. pombe SUMO/Pmt3
resembles SUMO in other organisms. However its N-terminus is
distinctly longer than those in S. cerevisiae SUMO/Smt3 or in
human SUMO-1/-2/-3 (Figure S1). While SUMO is essential for
viability in S. cerevisiae and mammals, deletion of the pmt3 gene is
not lethal, although null mutant cells are temperature sensitive for
growth and extremely sensitive to a range of toxins [22]. Mutants
defective in the S. pombe SUMO activator subunit (Rad31), the
SUMO conjugator (Hus5) or one of the SUMO ligases, Nse2, are
sensitive to DNA damaging agents [23,24,25,26]. In contrast, a
null mutant deleted for the S. pombe SUMO ligase Pli1 has little
phenotype, apart from a mild sensitivity to the microtubule
inhibitor thiabendazole (TBZ) [27].
Here we investigate sequence requirements for SUMO/Pmt3
function in S. pombe. We show that SUMO/Pmt3 is phosphory-
lated on serine residues at its extreme N-terminus and that
inability to phosphorylate SUMO/Pmt3 results in reduced levels
of total SUMO/Pmt3 and reduced levels of high Mr SUMO-
containing species in vivo. Additionally, we demonstrate that two
lysines (K14 and K30) are required for SUMO chain formation,
both in vitro and in vivo. A pmt3-K14R,K30R mutant shows cellular
abnormalities and sensitivity to HU, indicating that SUMO chain
formation is necessary for response to S phase arrest.
Results
S. pombe SUMO/Pmt3 is phosphorylated
As part of our investigation into sumoylated species in S. pombe
we undertook 2D PAGE. An example of a typical gel (using a low
level of protein, 50 mg, and isoelectric focussing range pH 3–6)
stained with colloidal Coomassie Blue is shown in Figure S2.
Western blotting of a similar 2D gel with anti-SUMO antisera
(Figure 1A) showed multiple species, including five which migrate
with pIs and Mr similar to that of SUMO/Pmt3. (S. pombe
SUMO/Pmt3 has a predicted pI of 4.6 and migrates at
approximately 18 kDa, e.g. [28]).
One possible explanation for the presence of these species is that
they could be intermediates arising during the processing of the
precursor form of SUMO/Pmt3 to the mature form. We therefore
compared the pattern of species in wild type and pmt3-GG cells
(where only the mature form of SUMO/Pmt3 is present)
(Figure 1B). No difference in the relative amount of the species
was observed indicating that the species do not represent
processing intermediates.
The pattern of the anti-SUMO antibody cross-reacting species
suggests that the species may represent modified forms of SUMO/
Pmt3. Since the forms are very similar in size, but have different
pIs, it could be postulated that the modifying species is/are small,
but charged. One candidate for such a modifying species is
phosphate. To determine whether any of these species represent
phosphorylated forms, we treated protein extracts with calf
intestinal phosphatase (CIP) before analysis by 2D PAGE.
Figure 1B and Figure 2 indicate that two prominent acidic forms
(A,B) are lost following CIP treatment, consistent with them being
phosphorylated forms.
We next analysed the SUMO/Pmt3 sequence for possible
phosphorylation sites (Ser or Thr residues). Figure 2 shows that
SUMO/Pmt3 has nine Ser residues and eight Thr residues
(Figure 2, left hand panel). To identify which of these residues is
phosphorylated, we created a series of mutations in pmt3 (pmt3-1 -
pmt3-8) and used 2D PAGE to analyse the pattern of species
present in each mutant (Figure 2, right hand panel). In all mutants
the Ser or Thr residues were mutated to alanine. As a control we
included a wild type extract treated with CIP. Of the eight mutants
tested, seven had a similar number of species to that observed in
wild type cells. In only one mutant, pmt3-1 (pmt3-S2A,S4A,S6A), did
the pattern of species resemble that observed following treatment
with CIP. This indicates that phosphorylation occurs at the N-
terminus of SUMO/Pmt3, likely on two of the three Ser residues
(S2, S4, S6).
We next investigated whether inability to phosphorylate the N-
terminus of SUMO/Pmt3 affected the levels of high Mr SUMO-
Figure 1. Western analysis of 2D PAGE of S. pombe proteins. A. 50 mg of a wild-type total cell extract was separated by IEF (pH 3–6) followed
by SDS-PAGE (12.5%) and Western blotted with anti-SUMO antisera. Boxed region is an expanded version of a longer exposure of the same blot. B.
Comparison of species in extracts from wt, pmt3-GG and wt extracts+CIP (5 units/50 mg protein). * presumed forms of SUMO monomer, A,B, forms
not observed after CIP treatment , # possible acetylated form.
doi:10.1371/journal.pone.0006750.g001
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containing species in cells. The pmt3-1 mutant is the only mutant
of the eight that we tested that has altered levels of these high Mr
species (Figure 3A). In pmt3-1 the level of high Mr SUMO-
containing species is similar to the level observed in pmt3-nfl cells
(encoding a version of Pmt3 deleted for the first 29 aa), but is still
greater than that observed in the SUMO ligase null mutant pli1-d.
To determine whether the reduced level of high Mr species in
pmt3-1 cells was due to reduced levels of total SUMO, or reduced
ability to incorporate SUMO into chains we compared the levels of
free SUMO/Pmt3 in the Ser/Thr mutants and pli1-d with that in
wild type (Figure 3B and data not shown). Of all the mutants tested,
only pmt3-1 has reduced levels of free SUMO/Pmt3. This was not
observed with pli1-d cells, where the absence of a SUMO ligase
reduces the level of high Mr SUMO-containing species, but not the
total amount of SUMO within cells. This suggests that the inability
to phosphorylate SUMO/Pmt3 in pmt3-1 cells affects its stability,
and hence the amount of SUMO/Pmt3 available for sumoylation.
pmt3-1 is not sensitive to DNA damaging agents
We were interested to determine whether inability to phosphor-
ylate SUMO/Pmt3 affected the response of cells to DNA damaging
agents and other stresses. pmt3-1 is not sensitive to HU, MMS, CPT
or TBZ (Figure 4) or UV, IR or 1M sorbitol (data not shown),
despite having significantly reduced levels of high Mr SUMO-
containing species and free SUMO/Pmt3. This lack of phenotype is
reminiscent of pli1-d cells which also have little sensitivity to these
agents, apart from slight sensitivity to TBZ (Figure 4 and [27])
pmt3-2 is sensitive to camptothecin and MMS
Analysis of the sensitivities of the remaining seven pmt3 mutants,
(pmt3-2 – pmt3-8) (Figure 4) indicates that pmt3-2 (pmt3-S15A) is
sensitive to the topoisomerase I inhibitor, camptothecin (CPT),
and slightly sensitive to MMS. The reason for this is not known
but may reflect a requirement for S15 in a process required for
replication of a damaged DNA template.
Sequence requirements for SUMO chain formation
The N-termini of S. cerevisiae SUMO/Smt3 and human SUMO-
2/3 contain lysine residues that are involved in SUMO chain
formation. Specifically, mutational analysis indicates that the major
branch sites used during SUMO chain formation are K15 and K11
in S. cerevisiae Smt3 and human SUMO-2/3 respectively [17,19,20].
These lysine residues both occur within the SUMO acceptor
consensus motif, yKxE. The N-terminal region of S. pombe SUMO/
Pmt3 does not contain a KxE motif (Figure S1). This suggests that
the sequence requirement(s) for SUMO chain formation may be less
Figure 2. Position of serine and threonine residues and effects of mutations in SUMO/Pmt3. Position of serine and threonine residues in
SUMO/Pmt3 are indicated by stars. Left hand panel: sites of mutations in pmt3 mutants. Right hand panel: Western analysis with anti-SUMO antisera
of 2D PAGE (1st dimension pH range 3–6, 2nd dimension 12.5% acrylamide) of extracts from wild type (wt), wild type+CIP and pmt3 mutants. A,B,
forms not observed after CIP treatment, # possible acetylated form.
doi:10.1371/journal.pone.0006750.g002
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stringent in S. pombe than in other organisms. Instead, SUMO/Pmt3
contains the sequence DVKPST (aa 28–33), adjacent to the highly
conserved region of the molecule, and which corresponds to
EVKPET (aa 17–22) in S. cerevisiae. In addition to K30, SUMO/
Pmt3 has another lysine residue (K14) in its N-terminus. We have
previously shown that K30 can act as a SUMO acceptor for chain
formation in S. pombe [26]. We also demonstrated that the SUMO
ligase, Nse2, can enhance SUMO chain formation.
We were interested in whether K14 can also be used as a SUMO
acceptor, and whether the other S. pombe SUMO ligase, Pli1, can
facilitate SUMO chain formation. Figure 5A indicates that under our
standard in vitro SUMO modification conditions in the absence of
either of the SUMO ligases, Nse2 or Pli1, mutation of lysine 14 to
arginine (Pmt3-K14R) (lane 2), results in a similar decrease in SUMO
chain formation as is observed with Pmt3-K30R (lane 3) when
compared to wild type SUMO/Pmt3 (lane 1). Replacement of both
lysine residues with arginine (Pmt3-K14R,K30R) further decreases
chain formation (lane 4). These results indicate that both K14 andK30
act as SUMO acceptors in vitro, and that it is unlikely that there are
other lysine residues within SUMO/Pmt3 involved in chain formation.
We next compared the effect of the K14R, K30R and
K14R+K30R mutations on chain formation facilitated by the
two SUMO ligases. Figure 5B shows that, as previously described
[26], using Nse2 as a ligase, chain formation is reduced with Pmt3-
K30R (lane 7) when compared to wild type Pmt3 (lane 3). Using
Pmt3-K14R (lane 5) chain formation is also reduced, but to a
somewhat lesser extent than with Pmt3-K30R (lane 7). Mutation
of both lysines (Pmt3-K14R,K30R) essentially abolishes chain
formation (lane 9). When Pli1 is used as a ligase, there is only a
small reduction in chain formation with either Pmt3-K14R
(Figure 5C, lane 4) or Pmt3-K30R (lane 6) as compared to wild
type Pmt3 (lane 2). As is observed with Nse2, mutation of both
lysine residues (Pmt3-K14R,K30R, lane 8) abolishes chain
formation. Taken together, these results show that both K14
and K30 can act as SUMO acceptor sites in vitro when chain
formation is facilitated by either of the SUMO ligases. Since
mutation of both residues abolishes chain formation, it is likely that
K14 and K30 are the only SUMO acceptor sites in SUMO/Pmt3.
Inability to form SUMO chains results in aberrant cellular
morphology and sensitivity to hydroxyurea
We were next interested in determining whether any of the pmt3
K to R mutations affect SUMO modification or chain formation
when the mutant alleles are present in cells as the sole copy of
Figure 3. Effect of pmt3 mutations on levels of sumoylated species and free SUMO/Pmt3 in vivo. A. Western blot 7.5% SDS PAG of total
cell extracts from wt, pli1-d and pmt3 mutant cells as indicated, probed with anti-SUMO antisera (upper panel) and anti-tubulin antisera (lower panel).
B. Western blot 12.5% SDS PAG of total cell extracts from wt, pli1-d and pmt3 mutant cells as indicated, probed with anti-SUMO antisera (upper panel)
and anti-tubulin antisera (lower panel).
doi:10.1371/journal.pone.0006750.g003
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SUMO/Pmt3 and whether they affect cell viability or morphol-
ogy. All three mutants are viable, although pmt3-K14R,K30R
colonies grow slightly slower than wild type (data not shown).
Western blotting with anti-SUMO antisera indicates that,
compared to wild type, pmt3-K14R has substantially reduced levels
of high Mr SUMO-containing species (Figure 6A, lanes 2),
compared to wild type cells (lanes 1,5). Cells containing pmt3-K30R
(lane 3) have a similar level of high Mr SUMO/Pmt3-containing
species to that observed in wild type cells (lanes 1,5), but the double
mutant pmt3-K14R,K30R has significantly reduced levels high Mr
species (lane 4), intermediate between those observed in pli1-d and
hus5-62 cells (defective in the SUMO conjugator, [24,25]). These
data show that K14 and, to a lesser extent, K30 are required for
SUMO chain formation in vivo.
Mutants defective in sumoylation e.g. rad31-d (deleted for one
subunit of the SUMO activator [23]) and hus5-62 have aberrant
cell and nuclear morphologies under normal growth conditions,
and are sensitive to DNA damaging agents and the DNA synthesis
inhibitor hydroxyurea (HU) [24,25]. Comparison of the morphol-
ogies of pmt3-K14R and pmt3-K30R with that of wild type cells,
indicates that replacement of a single lysine residue has no effect
on cell or nuclear morphology, as cells resemble wild type
(Figure 6B). However pmt3-K14R,K30R cells display a range of
cellular morphologies, including elongated cells, aberrant nuclear
structure (labelled a) and stretched and fragmented chromatin
(labelled b). This phenotype is reminiscent of the phenotypes of
rad31-d and hus5-62 cells [23,24,25] and indicates that SUMO
chain formation is important for normal growth under vegetative
conditions.
We next investigated whether any of these pmt3 mutants were
sensitive to HU or other toxins. All the SUMO chain mutants
resemble wild type in their response to UV, MMS, CPT and TBZ
(Figure 6C and data not shown). The pmt3-K14R and pmt3-
K14R,K30R mutants are both sensitive to HU (5 mM), while pmt3-
K30R is very slightly sensitive to HU. These data indicate that
K14, and possibly K30, is required for response of cells to
replication arrest. The HU sensitivities of pmt3-K14R and pmt3-
K14R,K30R are significantly less than that observed for hus5-62,
indicating that as well as a requirement for SUMO chains,
modification of target proteins by single SUMO/Pmt3 moieties is
also likely to be necessary for the response to S phase arrest.
Discussion
We show here that SUMO/Pmt3 is phosphorylated at its
extreme N-terminus. While this manuscript was in preparation,
results from mass spectrometry studies were published [29] which
indicate that human SUMO-1 and S. cerevisiae SUMO/Smt3 are
phosphorylated on S2. Our results described here, which show
that S. pombe SUMO/Pmt3 is likely phosphorylated on two of
three serine residues, S2, S4 and S6 (or diphosphorylated on one
of them), are consistent with these data. [29]. In addition to being
phosphorylated, Matic et al. observed that SUMO is acetylated on
its N-terminus. Acetylation of SUMO/Pmt3 would account for
the species labelled # (Figures 1 and 2) that remains after
treatment with CIP.
Interestingly, inability to phosphorylate SUMO/Pmt3 in pmt3-
1, results in a reduction in the level of high Mr SUMO containing
species. Despite this, pmt3-1 cells grow as wild type and are not
sensitive to DNA damaging agents, HU or TBZ. Another feature
of pmt3-1 cells is the reduced level of free SUMO/Pmt3 (Figure 3B)
suggesting that phosphorylation of SUMO/Pmt3 is required for
stability of the molecule. The fact that pli1-d cells have normal
levels of free SUMO/Pmt3 indicates that the low level of free
SUMO/Pmt3 in pmt3-1 is not likely to be due to the fact that in
these cells, it is inefficiently conjugated onto target molecules.
It is now well documented that SUMO is capable of forming
chains [17,18,20,30] and reviewed in [31]. We show here that S.
pombe SUMO/Pmt3 can form chains using two lysine residues in the
N-terminus (K14 and K30). Interestingly, the K30R mutation has a
Figure 4. Effect of pmt3 mutations on sensitivity to DNA damaging agents, HU and microtubule inhibitors. 10 ml of 10 fold serial
dilutions were plated onto media as indicated, and incubated at 30uC for 5 days.
doi:10.1371/journal.pone.0006750.g004
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Figure 5. Pmt3 sequence requirements for chain formation. A–C. Mutant forms of Pmt3 tested for ability to form Pmt3 chains using the in
vitro sumoylation assay in the absence of target protein. A. Lanes 1 Pmt3-GG, Lane 2 Pmt3-K14R,GG, Lane 3 Pmt3-K30R,GG, lane 4 Pmt3-
K14R,K30R,GG, lane 5 no Pmt3. Reactions were carried out with 3 mg Hus5. B. Lane 1 3 mg Hus5, Lanes 2–9 0.3 mg Hus5, otherwise as indicated. C.
Lanes 1–8 0.3 mg Hus5. * indicates cross-reaction with SAE proteins. H5-SUMO represents sumoylated Hus5.
doi:10.1371/journal.pone.0006750.g005
SUMO Chains
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somewhat greater effect on Nse2-dependent chain formation [26]
than it does on Pli1-dependent chain formation (Figure 5B,C). The
reason for this is not known, i.e. whether it reflects the fact that the
two SUMO ligases have different specificities, or whether Pli1
behaves in a more promiscuous manner and can select K14 as an
acceptor site if K30 is mutated. The sensitivities of the three SUMO
Figure 6. Phenotype of mutants defective in SUMO/Pmt3 chain formation. A. Western analysis of total cell extracts from cells containing
mutant versions of SUMO/Pmt3. Lane 1,5 wt, lane 2 pmt3-K14R, lane 3 pmt3-K30R, lane 4 pmt3-K14R,K30R, lane 6 pli1-d, lane 7 hus5-62. B. Morphology
of methanol fixed cells, stained with DAPI and calcofluor. C. Phenotype of pmt3 mutants. 10 ml of 10 fold serially diluted cultures were plated onto
media as indicated, and incubated at 25uC for 5 days.
doi:10.1371/journal.pone.0006750.g006
SUMO Chains
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chain mutants to HU, but not to a range of other genotoxins
indicates a role for SUMO chains in the cell’s response to S phase
arrest. The fact that pmt3-K14R,K30R cells have aberrant cell and
nuclear morphologies, while the two single mutants appear
morphologically wild type indicates a role for both lysine residues.
The morphology of pmt3-K14R,K30R is reminiscent of rad31-d and
hus5-62 mutants [23,24,25]. These results are in contrast to what
has been observed in S. cerevisiae, where an smt3-allRmutation has no
effect on vegetative growth or sensitivity to toxins [20].
It has recently been shown that SUMO chains interact with
STUbLs, and can be ubiquitinated by them [21]. If one of the
functions of chain formation is to facilitate the interaction of
SUMO/Pmt3 with the STUbLs it might be expected that the
phenotype of a mutant defective in chain formation would share
similarities with the phenotypes of STUbL mutants. In S. pombe the
STUbL proteins include Slx8, Rfp1 and Rfp2 [14,32]. Deletion of
slx8 or of both rfp1 and rfp2 is lethal, while a conditional mutant of
slx8 (slx8-1) is sensitive to HU, MMS and CPT [14]. pmt3-
K14R,K30R has a similar sensitivity to HU as slx8-1, but is wild
type for response toMMS and CPT. The reason for the difference in
MMS and CPT sensitivity between slx8-1 and the SUMO chain
mutants could be explained if the S. pombe STUbLs do not necessarily
need to interact with SUMO chains in order to be targeted to
substrates, but could recognise single SUMO species. This would be
consistent with the fact that unlike the human STUbL, RNF4, that
contains multiple SIMs which are proposed to recognise SUMO
chains [21], S. pombe STUbLs only contain one or two SIMs [14,32],
suggesting that they interact with mono-sumoylated species.
In summary, the N-terminus of SUMO/Pmt3 is required for
the formation of SUMO chains and is phosphorylated. Surpris-
ingly, a pmt3 allele encoding a non-phosphorylatable version of
SUMO/Pmt3 behaves as wild type. In contrast, abolition of
SUMO chain formation has a substantial effect on cell and nuclear
morphology. In particular, SUMO chain formation is required for
a process associated with S phase arrest, perhaps involving the
STUbLs. The precise role of SUMO chains in this event i.e. the
identity of protein(s) required for the response to S phase arrest,
that are modified by SUMO chains remains to be determined.
Materials and Methods
Strains and plasmids
Strains were constructed using standard genetic techniques. The
pli1-d mutant was created by deleting the ORF using the method
of Bahler et al. [33], hus5-62 was from A. Carr, Sussex [24]. Full
length pmt3 and pmt3-GG were amplified as described in [28].
pmt3-nfl, lacking the coding sequence for 29 aa at the N terminus,
was produced by PCR. pmt3 mutant alleles were produced by
Quikchange PCR mutagenesis (Stratagene) according to the
manufacturer’s instructions. Mutant pmt3 alleles were subsequently
subcloned into pET15b (Novagen) for expression in E. coli, or
integrated into the S. pombe genome along with 0.5 kb 59 and 39
pmt3 flanking sequences and the ura4 gene as selectable marker.
Protein and Immunological methods
Whole cell S. pombe extracts were prepared using TCA as
described in [34]. 1D SDS PAGE and Western blotting was carried
out as described in [35]. 2D PAGE was undertaken using standard
techniques [36]. Total cell protein from 10OD595 units of cells were
precipitated with TCA. The precipitate was resuspended in ice-cold
acetone and protein precipitated at 4uC for 30 min. The precipitate
was harvested by centrifugation at 13 krpm for 30 min, and allowed
to dry. The pellet was resuspended in rehydration buffer (9M urea,
4% CHAPS, 2% IPG buffer (25 ml/mg pellet). DTT was added to
0.5%. 50 mg protein was added to modified rehydration buffer (6M
urea, 2M thiourea, 2% CHAPS, 2% IPG buffer) to produce a total
volume of 125 ml. 7 cm IPG strips pH 3–6 were used for the first
dimension. 12.5% acrylamide was used for the second dimension.
Anti-SUMO/Pmt3 antiserum was produced against full length
SUMO/Pmt3 using standard methods [35]. Western analysis using
purified recombinant proteins indicates that the antisera recognises
equally well full length SUMO/Pmt3, N-terminally truncated
SUMO/Pmt3 (Pmt3-nfl), Pmt3-1, and Pmt3 K to R mutants
(Figure S3). Monoclonal anti-tubulin antibodies were from Sigma.
The in vitro sumoylation assay was used as described previously [28].
Phenotypic analysis of mutants
Sensitivities to hydroxyurea (HU), methyl methanesulphonate
(MMS), camptothecin, (CPT) and thiabendazole (TBZ) were
analysed on YEP agar at the doses stated. Plates were incubated at
30uC or 25uC for 5 days as stated. Cell morphology was analysed
using methanol-fixed cells stained with DAPI (1 mg/ml) and
calcofluor (0.5 mg/ml) using an Applied Precision Deltavision
Spectris microscope.
Supporting Information
Figure S1 SUMO sequence alignments Comparison of S. pombe
(Sp), S. cerevisiae (Sc), human (Hs), D. melanogaster (Dm) and C. elegans
(Ce) SUMO sequences, created using the ClustalW program.
* indicates K14 and K30
Found at: doi:10.1371/journal.pone.0006750.s001 (9.49 MB TIF)
Figure S2 2D PAGE of total S. pombe proteins. 50 mg of a wild-
type total cell extract was separated using IEF strip pH 3–6,
followed by SDS PAGE (12.5% acrylamide). Gel was stained with
colloidal Coomassie Blue.
Found at: doi:10.1371/journal.pone.0006750.s002 (9.29 MB TIF)
Figure S3 Anti-SUMO antisera recognise wt and mutant
SUMO/Pmt3 Coomassie Brilliant Blue (CBB) staining and
western analysis of recombinant wild type and mutant SUMO/
Pmt3 with anti-SUMO antisera.
Found at: doi:10.1371/journal.pone.0006750.s003 (9.42 MB TIF)
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